MaxLinear (MXL) has had the highest return since March 30, 2026 by a mid-cap US stock, returning 314.8%.
| ASSET | % RETURN |
|---|---|
MaxLinear (MXL) | 314.77% |
Penguin Solutions (PENG) | 221.3% |
Maase (MAAS) | 215.44% |
SharonAI Holdings, Inc Class A Common Stock (SHAZ) | 183.36% |
BlackBerry (BB) | 169.4% |
Uniqure (QURE) | 165.64% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 162.83% |
Sellas Life Sciences (SLS) | 157.27% |
Oscar Health (OSCR) | 152.37% |
Clover Health Investments (CLOV) | 151.16% |
Sezzle (SEZL) | 149.01% |
Crinetics Pharmaceuticals (CRNX) | 148.9% |
Silicon Motion Technology (SIMO) | 145.64% |
Definium Therapeutics (DFTX) | 144.87% |
Liquidia Technologies (LQDA) | 144.73% |
AMC Entertainment (AMC) | 136.46% |
Maravai Lifesciences Holdings (MRVI) | 135.54% |
10X Genomics (TXG) | 135.47% |
Dave (DAVE) | 130.02% |
Xometry (XMTR) | 129.98% |
Organon (OGN) | 128.72% |
Aehr Test Systems (AEHR) | 125.87% |
Vishay Intertechnology (VSH) | 123.3% |
MBX Biosciences, Inc Common Stock (MBX) | 117.54% |
ChronoScale (CHRN) | 114.79% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.